Medicus Pharma Expands BCC Clinical Study into UK

Medicus Pharma Ltd. has announced its receipt of full regulatory and ethical approvals to expand the Phase 2 clinical study, SKNJCT-003, into the United Kingdom. This study explores the use of Doxorubicin Microneedle Array (D-MNA) for non-invasive treatment of basal cell carcinoma (BCC) of the skin. The approvals were granted by the UK's Medicines and Healthcare products Regulatory Agency and other ethical boards.

The study, which began in the United States, will now include UK sites to enhance patient recruitment and data collection for global clinical trials. The randomized, double-blind study involves 90 participants and tests varying doses of D-MNA against a placebo. Initial findings showed a positive trend with over 60% clinical clearance, although results are pending until the study's completion.

The UK expansion is part of Medicus's broader strategy to establish a global presence, aiming at a significant market opportunity in BCC treatment. The company is simultaneously pursuing other clinical trials and strategic partnerships to advance its therapeutic offerings.